Aktie A1416X INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Innovative Pharmaceutical Biotech Limited

Aktien

A1416X

BMG4783W1073

399

Markt geschlossen - Hong Kong S.E.
Andere Börsenplätze
 10:08:08 27.06.2024 		% 5 Tage % 1. Jan.
0,24 HKD 0,00 % Intraday Chart für Innovative Pharmaceutical Biotech Limited -15,79 % +9,59 %
26.06. Innovative Pharmaceutical erneuert THU-Vereinbarung und revidiert Zeitplan für die Kommerzialisierung des Produkts MT
25.06. Innovative Pharmaceutical Biotech Limited informiert über den Stand der Kommerzialisierung des oralen Insulinprodukts (das "Produkt") und die jüngste Geschäftsentwicklung der Gruppe CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Innovative Pharmaceutical Renews THU Agreement, Revises Product's Commercialization Timeline
Innovative Pharmaceutical Biotech Limited Provides Update on the Status of the Commercialization of the Oral Insulin Product (The "Product") and the Latest Business Development of the Group
Innovative Pharmaceutical Biotech Limited announced that it has received HKD 55.5 million in funding
Innovative Pharma Extends Long Stop Date for Convertible Bond Issuance
Innovative Pharmaceutical Biotech Returns to Fiscal H1 Attributable Profit
Innovative Pharmaceutical Biotech Limited Reports Earnings Results for the Half Year Ended September 30, 2023
Innovative Pharmaceutical Biotech to Return to Profit in Fiscal H1
Innovative Pharmaceutical Biotech Limited Provides Unaudited Earnings Guidance for the Six Months Ended 30 September 2023
Innovative Pharmaceutical Biotech Limited Announces Change of Address of Principal Place of Business in Hong Kong
Innovative Pharmaceutical Eyes Majority Stake in US Neurotechnology Firm
Innovative Pharmaceutical Biotech Limited entered into a memorandum of understanding to acquire a majority interest in Niraxx Light Therapeutics, Inc.
Innovative Pharmaceutical Plans HK$55.5 Million Bond Issue
Innovative Pharmaceutical to Raise HK$58 Million From Deal with US Firm Genuine Marketing
Innovative Pharmaceutical Biotech Limited announced that it expects to receive HKD 55.5 million in funding
Innovative Pharmaceutical Biotech Limited Appoints Cheng Tak Yiu as an Executive Director
Innovative Pharmaceutical Biotech Incurs Loss in Fiscal Year 2023
Innovative Pharmaceutical Biotech Limited Reports Earnings Results for the Full Year Ended March 31, 2023
Innovative Pharmaceutical Biotech Mulls Over Capital Injection in Technical Services Company
Innovative Pharmaceutical Biotech Limited Reports Earnings Results for the Half Year Ended September 30, 2022
Innovative Pharmaceutical Biotech Forecasts Swing to Loss in April-September Period
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A1416X Aktie
  4. Nachrichten Innovative Pharmaceutical Biotech Limited
  5. Andere Sprachen